The Cholesterol Claims FDA Actually Authorized

which authorized health claims exist under 101.75, 101.77, 101.81, 101.82 and 101.83?

Five authorized health claims under FDA's rules touch cholesterol, and we counted them straight off FDA's own subpart E list rather than trust a summary. 21 CFR 101.75 covers dietary saturated fat and cholesterol and risk of coronary heart disease (CHD). 101.77 covers fiber-containing grain products, fruits and vegetables and risk of CHD. 101.81 covers soluble fiber from certain foods and risk of CHD. 101.82 covers soy protein and risk of CHD. 101.83 covers plant sterol and stanol esters and risk of CHD.

All five are diet claims, not product claims.

The same subpart authorizes zero comparable claims for eyes, ears or nerves, which makes cholesterol's five look generous — until you read what each one actually lets you say, which is nothing about a pill's own cholesterol-lowering effect, only about a diet pattern.

why is 'may reduce the risk of coronary heart disease' not the same as lowering cholesterol?

Because FDA closed that door on purpose, in the same rulemaking that created the five authorized claims above. In its 2000 final rule, FDA wrote that "FDA continues to believe that 'lowers cholesterol,' however qualified, is an implied disease claim." No hedge word rescues the sentence: attach 'helps,' 'may' or 'supports' to 'lowers cholesterol' and it still reads as treating a disease, because lowering elevated cholesterol is inseparable from treating heart disease in the public mind.

FDA doesn't stop at the sentence, either. It states plainly that "FDA will review all cholesterol claims to determine whether the labeling as a whole implies that the product is intended to lower elevated cholesterol levels," which means a bottle can print the right eleven words on the panel and still fail if the surrounding page, imagery or brand name argue the opposite point.

The risk-reduction claims describe a diet pattern, never a capsule you swallow.

what qualifying conditions does each substance have to meet first?

Each of the five claims carries its own qualifying condition written into the regulation text, and none of them is a flat 'contains the ingredient' bar.

We don't have the exact gram and milligram cutoffs verified against current regulation text for this page. Retrieving the full text of 101.75, 101.77, 101.81, 101.82 and 101.83 directly from eCFR's subpart E is what would settle each number before you put one in ad copy.

• 101.75 (saturated fat and cholesterol): the food itself has to be low in saturated fat, low in cholesterol and low in total fat.
• 101.77 (fiber-containing grain products, fruits and vegetables): the same low-fat, low-cholesterol baseline, plus a minimum fiber content.
• 101.81 (soluble fiber): a minimum per-serving amount of soluble fiber from an eligible source such as oat bran or psyllium.
• 101.82 (soy protein): a minimum grams-per-serving level of soy protein.
• 101.83 (plant sterol and stanol esters): a minimum daily milligram intake of the ester, taken with meals.

can a multi-ingredient capsule use a claim written for a food substance?

In practice, almost never — and that surprises people who assume an authorized claim is a green light for any product containing the substance. Each of the five claims is written around a food meeting a specific dosage and food-matrix condition, not around 'contains soy protein' or 'contains plant sterols' as a bare formulation fact.

We checked the enforcement letters cited elsewhere in our research — BergaMet North America's 'Cholesterol Command' capsule and the Essential Elements letter, both from FDA's November 2022 cholesterol sweep — and both show capsules making unauthorized lowering claims, never an authorized risk-reduction claim that got rejected on a technicality. That absence is itself informative: the qualifying conditions on saturated fat, cholesterol and total fat content describe the whole food product carrying the claim, something a margarine or a cereal box has and a supplement capsule structurally doesn't, so the claim has nowhere to attach even before you reach the dosage threshold for the sterol, fiber or protein itself. If you're building a cholesterol angle around one of these five claims rather than around the maintenance wording covered below, you're likely reaching for a door built for a different kind of product.

Plant sterols are the closest fit on paper, since sterol and stanol esters do appear in capsule and chew formats elsewhere in the market.

serious-disease flag: why does fda treat hypercholesterolemia as the disease itself?

FDA treats hypercholesterolemia, the clinical name for elevated blood cholesterol, as the disease itself rather than a risk factor for one, and it says so in plain terms. In the same 2000 rule, FDA wrote that "elevated blood pressure (hypertension) and elevated cholesterol (hypercholesterolemia) are diseases themselves, with subsequent events (heart attack, stroke) the late consequences of those diseases."

That single sentence sets a lower ceiling for cholesterol copy than most operators assume. We cover the mechanics of that ceiling on our page on how FDA classifies high cholesterol as a disease, and it's the reason the five authorized claims above never mention a supplement directly.

Addressing the number is addressing the disease — there's no gap to write into.

how does an authorized claim interact with the 'already within the normal range' wording?

They run on separate tracks entirely, and mixing them up is a common drafting mistake in this niche. An authorized health claim under subpart E is a diet-disease relationship statement built for a food: a diet low in saturated fat and cholesterol may reduce the risk of coronary heart disease is the model shape. A structure/function claim is different: FDA's own model sentence for a supplement is that it "helps to maintain cholesterol levels that are already within the normal range," carrying the mandatory not-evaluated-by-FDA disclaimer instead of any disease reference.

The 'already normal' wording only protects someone whose cholesterol isn't elevated in the first place, which is a narrow claim to build a funnel around.

what does a compliant cholesterol angle look like once lowering is off the table?

Once lowering is off the table, what's left for a capsule is narrow: describe a level that's already normal, and stop there. The maintenance wording covered above only works for someone whose cholesterol isn't elevated, which cuts against the actual audience most cholesterol offers are built to reach. The same grammar move is accepted elsewhere in the same rule, on the calm and stress claims FDA listed as acceptable: describe the normal state, never promise to fix the abnormal one.

FTC applies the same skepticism to hedged versions of a lowering claim. Its Health Products Compliance Guidance walks through a company advertising that preliminary studies show its product 'may be effective in reducing cholesterol' off the back of two thin studies — roughly the same standard FDA applies, treating a soft hedge as no cure for weak evidence.

The safest claim in this niche is also the smallest one.

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For external context, readers should compare advertising and research decisions against authoritative primary references such as FTC health claims guidance, Meta advertising standards, and Meta Ad Library. Daily Intel adds the proprietary direct-response layer: blackhat, greyhat, and whitehat campaign pattern comparison across VSL-heavy niches and 14+ language markets.

For deeper evaluation, continue through Nutra niche intelligence directory, Compounded GLP-1 in 2026: What's Still Legal Now That the Shortage Is Over, 'Nature's Ozempic': Where Berberine Marketing Crosses the Legal Line, GLP-1 Telehealth Affiliate Offers: The 2026 Risk Map Before You Send Traffic, GLP-1 Support Supplements: The Compliant Way Into the Biggest Demand Curve in Nutra, and GLP-1 affiliate marketing intelligence. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.